Last reviewed · How we verify
Allogenic Mesenchymal Stromal Cells
At a glance
| Generic name | Allogenic Mesenchymal Stromal Cells |
|---|---|
| Also known as | Mesenchymal stem cells (MSC), MSC injection, MSV (MSV=MSC prepared following Valladolid IBGM procedure) |
| Sponsor | Red de Terapia Celular |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS (PHASE2)
- Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells (PHASE1)
- Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis (PHASE1, PHASE2)
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease (PHASE1)
- Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial (PHASE1, PHASE2)
- Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study (PHASE1, PHASE2)
- ASCs in Recently Diagnosed Non-ischemic Heart Failure (PHASE2)
- A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allogenic Mesenchymal Stromal Cells CI brief — competitive landscape report
- Allogenic Mesenchymal Stromal Cells updates RSS · CI watch RSS
- Red de Terapia Celular portfolio CI